Compare Incyte Corporation (INCY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Yum! Brands, Inc. — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: Yum! Brands, Inc. is the larger of the two by market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Yum! Brands, Inc. for 132 Days on average.
| INCY | YUM | |
|---|---|---|
Market Cap | $22.85B | $39.02B |
Volume | 1,927,029 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $168.16 |
52-Week Low | $83.80 | $135.77 |
Typical Hold Time | 33 Days | 132 Days |
Enterprise Value | $18.35B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
YUM trades at $144.82, up 3.18% today, with a bullish technical signal despite mixed indicators. Revenue grew to $8.21B in 2025, with net income of $1.56B and a strong net margin of 25.4%. The company recently sold Pizza Hut for $1.5B and announced a $0.75 dividend, reflecting strategic focus on core brands. Analysts maintain a consensus price target of $170.44, with 39% buy ratings.
YUM presents a stable investment with consistent earnings beats and dividend growth, but faces risks from high debt levels and competitive pressures. Upside is supported by analyst targets and operational efficiency, while macroeconomic headwinds and consumer spending trends pose challenges to sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
